Healthcare - Biotechnology - NASDAQ - US
$ 1.56
-8.77 %
$ 75.4 M
Market Cap
-1.07
P/E
Price Target
Average
220.51%
Revenue Forecast
Estimate
-0.00%
EBIT
Estimate
41.12%
Net Income
Estimate
17.28%
WALL STREET ESTIMATES
Wall Street Analysts Price Targets
BioAtla, Inc.
Wall Street analysts predict an average 1-year price target for BCAB of $5 , with forecasts ranging from a low of $5 to a high of $5 .
BCAB Lowest Price Target
Wall Street Target
5 USD
220.51%
BCAB Average Price Target
Wall Street Target
5 USD
220.51%
BCAB Highest Price Target
Wall Street Target
5 USD
220.51%
REVENUE FORECAST
Revenue Forecast Chart BCAB
EBIT FORECAST
EBIT Forecast Chart BCAB
NET INCOME FORECAST
Net Income Chart BCAB